Skip to main content
CourtGPT logoCourtGPT
Directory
Law
For Attorneys
Blog
AppointmentsSign InSign Up
§ 126-z-3 — New Hampshire Law | CourtGPT
  1. Home/
  2. Laws/
  3. New Hampshire/
  4. Title X - Public Health/
  5. Chapter 126-z - Terminal Patients' Right to Try Act/
  6. § 126-z-3
New Hampshire Legal Code

§ 126-z-3

Ask AI about this
[RSA 126-Z:3 effective until January 1, 2025; see also RSA 126-Z:3 set out below.] 126-Z:3 Liability of Physician; Facility. – I. Notwithstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based solely on a physician's recommendation to an eligible patient regarding or prescription for or treatment with an investigational drug, biological product, or device. II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based solely on the institution's participation in the treatment or use of an investigational drug, biological product, or device under this chapter. [RSA 126-Z:3 effective January 1, 2025; see also RSA 126-Z:3 above.] 126-Z:3 Liability of Physician; Facility. – I. Notwithstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to an eligible patient regarding or

shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based primarily on a physician's recommendation to an eligible patient regarding or prescription for or treatment with an investigational drug, biologic, or device. II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based primarily on the institution's participation in the treatment or use of an investigational drug, biologic, or device under this chapter. Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025.